Intensity Therapeutics, Inc.
INTS
$3.75
$0.010.27%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/27/2026
-
Zacks Investment Research
5/14/2026
-
PR Newswire
5/10/2026
-
The Cerbat Gem
5/7/2026
-
PR Newswire
5/1/2026
-
Zacks Investment Research
5/1/2026
-
Zacks Investment Research
4/16/2026
-
Zacks Investment Research
3/30/2026
-
TipRanks Financial Blog
3/29/2026
-
TipRanks Financial Blog
3/29/2026
-
TipRanks Financial Blog
3/27/2026
-
PR Newswire
3/24/2026
-
PR Newswire
3/13/2026
-
TipRanks Financial Blog
3/12/2026
-
PR Newswire
3/6/2026
-
Seeking Alpha - Healthcare
3/6/2026
-
SeekingAlpha.com: All News
3/6/2026
-
TipRanks Financial Blog
3/6/2026
-
The Fly
3/6/2026
-
PR Newswire
2/19/2026
-
TipRanks Financial Blog
2/19/2026
-
The Fly
2/13/2026
-
TipRanks Financial Blog
2/13/2026
-
Stocktwits News Feed
2/13/2026
-
The Fly
2/13/2026
-
PR Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, March 27, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
203 221 7381
Address
1 Enterprise Drive
Shelton, CT 06484-4779
Shelton, CT 06484-4779
Country
Year Founded
Business Description
Sector
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the...
more